CARYSIL CARYSIL Q3 FY25 results (Oct–Dec 2024) and concall
Carysil reported a mixed Q3 FY25, with robust revenue growth but significant margin compression driven by external factors and strategic investments. While core product volumes showed strong growth and new large orders were secured, profitability was impacted. Management outlined plans for margin recovery, capacity optimization, and strategic product diversification, particularly for the premium Sternhagen brand and the struggling US subsidiary.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 207 | 203 |
| EBITDA | 37 | 29 |
| Net profit | 17 | 13 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
